Drug profile · INN
sotagliflozin
ZYNQUISTA
sotagliflozin (ZYNQUISTA) is a sodium/glucose cotransporter 2 inhibitor. Associated with LEXICON PHARMACEUTICALS, INC.. Route of administration: oral. Current US regulatory status: approved.
Drug details — sotagliflozin
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- ORAL
- Patents
- 20
- Programs
- 16
- Data quality
- 0.89
Quick answer
sotagliflozin (ZYNQUISTA) is a sodium/glucose cotransporter 2 inhibitor. Associated with LEXICON PHARMACEUTICALS, INC.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium/glucose cotransporter 2 inhibitor
Primary target: Sodium/glucose cotransporter 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11730723
Compounds and methods for treating viral infections
granted -
US 9067962
Methods of treating diabetes
granted -
US 8772483
Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid
granted -
US 8772291
Multicyclic compounds and methods of their use
granted -
US 8658682
(E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone dihydrate and methods of its use
granted -
US 8497271
Modulators of G protein-coupled receptor 88
granted -
US 8476413
Sulfanyl-tetrahydropyran-based compounds and methods of their use
granted -
US 8426414
Modulators of G protein-coupled receptor 88
granted -
US 8410121
Methods of treating pulmonary hypertension
granted -
US 8404732
Methods of treating ulcerative colitis
granted -
US 8304577
Modulators of G protein-coupled receptor 88
granted -
US 8227661
Methods of identifying agents that ameliorate or modulate effects of PRO1328 gene disruptions
granted -
US 8217156
Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use
granted -
US 8153804
Aryl pyridines and methods of their use
granted -
US 8093267
Methods of treating rheumatoid arthritis
granted -
US 7998994
Solid forms of (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use
granted -
US 7897763
Process for the preparation of substituted phenylalanines
granted -
US 7855291
Process for the preparation of substituted phenylalanines
granted -
US 7825142
Heterocyclic compounds, compositions comprising them and methods of their use
granted -
US 7825150
Compositions and methods for treating immunological and inflammatory diseases and disorders
granted
Frequently asked questions
What is sotagliflozin?
sotagliflozin (ZYNQUISTA) is a sodium/glucose cotransporter 2 inhibitor. Associated with LEXICON PHARMACEUTICALS, INC.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sotagliflozin?
ZYNQUISTA is a marketed brand name for sotagliflozin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sotagliflozin?
sotagliflozin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.